Inclusion Criteria

          -  Must have relapsed or refractory metastatic squamous or nonsquamous non-small cell
             lung cancer (NSCLC) (without known targetable EGFR, ALK, ROS1, or BRAF mutations) or
             metastatic cutaneous melanoma (including participants without targetable gene
             mutations and BRAF-V600E/V600K participants who have failed targeted therapy)

          -  Participants must be currently on PD-1 checkpoint inhibitor (CPI) therapy (e.g.
             nivolumab or pembrolizumab) or had their last dose of PD-1 CPI within 90 days prior to
             enrollment; PD-1 inhibitor therapy must be the last previous line of therapy.

          -  Participants must have progressed on treatment with an anti-PD-1 monoclonal antibody
             (mAb) administered either as monotherapy, or in combination with other checkpoint
             inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of
             the following criteria.

               -  Participants with refractory disease must have progressed without a prior
                  objective response during or after prior PD-1 inhibitor therapy within 3 months
                  or have stable disease (SD) for <6 months OR

               -  Participants with relapsed diseased must have progressed after having developed a
                  prior objective response of CR/PR for at least 3 months or SD for at least 6
                  months AND

               -  Have received at least 2 doses of an approved anti-PD-1 mAb.

                    -  Have demonstrated disease progression (PD) after PD-1 as defined by RECIST
                       v1.1. Progressive disease has been documented within 90 days from the last
                       dose of anti-PD-1 mAb.

          -  Tumor tissue sample obtained within 3 months prior to enrollment is required, and no
             systemic anticancer therapy given after the sample was obtained.

          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status score of equal or less
             than 1

        Exclusion Criteria

          -  Has known active CNS metastases and/or carcinomatous meningitis.

          -  Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy
             within 4 weeks of first study drug dose.

          -  History of another malignancy within 3 years before the first dose of study drug or
             any evidence of residual disease from a previously diagnosed malignancy.